PD1/PDL1 checkpoint blockade therapy is part of the standard therapy for melanoma (48), but because of immune tolerance, it has resulted in poor clinical outcomes in some patients treated with PD-1 pathway blockade (49). This evidence concerns the gene CD274 and melanoma.